Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of flavonoid glycoside compound on medicine for treating cerebral apoplexy

A technology of flavonoid glycosides and compounds, applied in the field of medicine, can solve problems such as application of unseen compounds

Inactive Publication Date: 2013-01-16
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, taking a comprehensive look at domestic and foreign literature, there is no application of this compound in the treatment of ischemic brain injury.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of flavonoid glycoside compound on medicine for treating cerebral apoplexy
  • Application of flavonoid glycoside compound on medicine for treating cerebral apoplexy
  • Application of flavonoid glycoside compound on medicine for treating cerebral apoplexy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1: Extraction and separation of compounds 1

[0016] The whole herb of Clematis clematis collected from Huangnan Tibetan Autonomous Prefecture of Qinghai Province is used as raw material, dried in the shade, after being crushed, 4 kg of coarse powder is taken, and 12 liters of 70% ethanol is added to heat and reflux for extraction, a total of 3 extractions, 2 hours each time . The extracts were filtered and combined, concentrated and dried to obtain a total extract of 985.6 g. The extract was dispersed in 4 liters of water, extracted 3 times with petroleum ether, 4 liters each time, and the extracted water phase was extracted 4 times with n-butanol, 4 liters each time, the n-butanol extract was combined, and the solvent was recovered to obtain 168 grams of n-butanol extraction fraction. The n-butanol extraction part was subjected to silica gel column chromatography (silica gel H for thin-layer chromatography, Qingdao Ocean Chemical Factory), and the chloroform...

Embodiment 2

[0020] Example 2: Extraction and separation of compounds 2

[0021] The whole herb of Clematis clematis collected from Huangnan Tibetan Autonomous Prefecture of Qinghai Province is used as raw material, dried in the shade, after being crushed, 1 kg of coarse powder is taken, and 5 liters of 70% ethanol is added to heat and reflux for extraction, a total of 3 extractions, 4 hours each time . The extracts were filtered and combined, concentrated and dried to obtain 256.8 g of the total extract. The extract was dispersed in 1 liter of water, extracted 3 times with petroleum ether, 1 liter each time, the extracted aqueous phase was extracted 4 times with n-butanol, 1 liter each time, the n-butanol extract was combined, and the solvent was recovered to obtain 46 grams of n-butanol extraction fraction. The n-butanol extraction part was subjected to silica gel column chromatography (silica gel H for thin-layer chromatography, Qingdao Ocean Chemical Factory), and the chloroform-meth...

Embodiment 3

[0028] Example 3: Protective effect of compound APG on cerebral ischemia-reperfusion injury in rats

[0029] Purpose of the test: To observe the effect of the compound APG on the behavioral score and cerebral infarct size of rats with middle cerebral artery occlusion (MCAO), and to evaluate the protective effect of APG on cerebral ischemic injury.

[0030] Experimental animals: 60 male Sprague Dawley (SD) rats, weighing 250-280 g. Free to eat and drink, 25±2℃.

[0031] Reagents: APG, the compound of formula 1 in Example 1, 2,3,5-triphenyltetrazolium chloride (TTC, SigmaAldrich, USA), dimethyl sulfoxide (DMSO, SigmaAldrich, USA).

[0032] animal grouping

[0033] Divide into 6 groups, 8 in each group

[0034] (1) Sham operation group: 0.9% sodium chloride injection

[0035] (2) Model group: 0.9% sodium chloride injection

[0036] (3) Model + DMSO group: 20% DMSO sodium chloride solution

[0037] (4) Low dose group: 25mg / kg

[0038] (5) Medium dose group: 50mg / kg

[0039...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of a flavonoid glycoside compound on a medicine for treating cerebral apoplexy. A compound with a structure represented by a formula I is apigenin-7-O-beta-D-(6''-p-coumaroyl)-glucopy ranoside. The pharmacological test results prove that the compound has an obvious protection effect on ischemic injury caused by a middle cerebral artery occlusion (MACO) model and is free from toxic and side effects. The application of the flavonoid glycoside compound on the medicine for treating the cerebral apoplexy provided by the invention can provide a lead compound for preparing new medicines for protecting cerebral ischemic injury, so that the flavonoid glycoside compound can be a new medicine for treating the cerebral apoplexy.

Description

technical field [0001] The invention relates to the technical field of medicine, and relates to the application of a flavonoid glycoside compound in the preparation of a drug for treating cerebral apoplexy, specifically a flavonoid glycoside compound apigenin-7-O-β-D-(-6"-p- Application of coumaroyl)-glucopyranoside (apigenin-7-O-β-D-(-6″-p-coumaroyl)-glucopyranoside) in the preparation of drugs for treating ischemic cerebral apoplexy. Background technique [0002] Cerebral apoplexy (stroke) is the second leading cause of death in my country. Its high disability rate, mortality rate and recurrence rate seriously affect the quality of life of patients, endanger life and health, and cause huge burdens to families and society. Currently, for ischemic stroke, there is no clinically effective therapeutic drug or measure except for t-PA thrombolytic therapy. However, thrombolytic therapy has a strict time window limit, and only a very small number of patients can receive effective...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P9/10A61P25/00C07H17/07C07H1/08
Inventor 汤海峰熊利泽文爱东董海龙张伟蔡敏魏海东
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com